CA2848578A1 - Sperm protein as a detection biomarker of early stage ovarian cancer - Google Patents
Sperm protein as a detection biomarker of early stage ovarian cancer Download PDFInfo
- Publication number
- CA2848578A1 CA2848578A1 CA 2848578 CA2848578A CA2848578A1 CA 2848578 A1 CA2848578 A1 CA 2848578A1 CA 2848578 CA2848578 CA 2848578 CA 2848578 A CA2848578 A CA 2848578A CA 2848578 A1 CA2848578 A1 CA 2848578A1
- Authority
- CA
- Canada
- Prior art keywords
- patient
- gene
- ovarian cancer
- level
- expression level
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 102
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 100
- 108090000623 proteins and genes Proteins 0.000 title claims description 109
- 239000000090 biomarker Substances 0.000 title abstract description 15
- 238000001514 detection method Methods 0.000 title description 18
- 102000004169 proteins and genes Human genes 0.000 title description 13
- 101000824971 Homo sapiens Sperm surface protein Sp17 Proteins 0.000 claims abstract description 114
- 101000737052 Homo sapiens Coiled-coil domain-containing protein 54 Proteins 0.000 claims abstract description 113
- 238000000034 method Methods 0.000 claims abstract description 96
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 23
- 102100035167 Coiled-coil domain-containing protein 54 Human genes 0.000 claims description 104
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 94
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims description 93
- 230000014509 gene expression Effects 0.000 claims description 93
- 102100023123 Mucin-16 Human genes 0.000 claims description 85
- 239000000523 sample Substances 0.000 claims description 76
- 230000004083 survival effect Effects 0.000 claims description 47
- 238000011282 treatment Methods 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 25
- 238000002493 microarray Methods 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 9
- 239000008280 blood Substances 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 238000003753 real-time PCR Methods 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 7
- 241001465754 Metazoa Species 0.000 claims description 6
- 241000283690 Bos taurus Species 0.000 claims description 5
- 241000283073 Equus caballus Species 0.000 claims description 5
- 241001529936 Murinae Species 0.000 claims description 5
- 238000003364 immunohistochemistry Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 241000282465 Canis Species 0.000 claims description 3
- 238000007901 in situ hybridization Methods 0.000 claims description 3
- 239000013610 patient sample Substances 0.000 claims description 3
- 238000004393 prognosis Methods 0.000 abstract description 7
- 102100022441 Sperm surface protein Sp17 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 79
- 238000012360 testing method Methods 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 37
- 108020004414 DNA Proteins 0.000 description 33
- 201000011510 cancer Diseases 0.000 description 30
- 230000004044 response Effects 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000010099 disease Diseases 0.000 description 21
- 206010004433 Benign ovarian tumour Diseases 0.000 description 20
- 201000008016 ovarian benign neoplasm Diseases 0.000 description 20
- 230000003321 amplification Effects 0.000 description 17
- 238000003199 nucleic acid amplification method Methods 0.000 description 17
- 230000035945 sensitivity Effects 0.000 description 15
- 108091028043 Nucleic acid sequence Proteins 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 150000007523 nucleic acids Chemical group 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
- 238000003556 assay Methods 0.000 description 10
- 238000003757 reverse transcription PCR Methods 0.000 description 10
- 238000005259 measurement Methods 0.000 description 9
- 230000002611 ovarian Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000000137 annealing Methods 0.000 description 7
- 230000001413 cellular effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000013068 control sample Substances 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 230000036961 partial effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 108700028369 Alleles Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000036210 malignancy Effects 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 206010061289 metastatic neoplasm Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- -1 DNA or RNA Chemical class 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 102000000704 Interleukin-7 Human genes 0.000 description 4
- 108010002586 Interleukin-7 Proteins 0.000 description 4
- 206010061309 Neoplasm progression Diseases 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 230000005751 tumor progression Effects 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000000835 electrochemical detection Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000007855 methylation-specific PCR Methods 0.000 description 3
- 238000007857 nested PCR Methods 0.000 description 3
- 239000002853 nucleic acid probe Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000037821 progressive disease Diseases 0.000 description 3
- 238000010791 quenching Methods 0.000 description 3
- 230000000171 quenching effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000007861 thermal asymmetric interlaced PCR Methods 0.000 description 3
- 108091093088 Amplicon Proteins 0.000 description 2
- 108091029523 CpG island Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 238000000018 DNA microarray Methods 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 206010071602 Genetic polymorphism Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 102000003735 Mesothelin Human genes 0.000 description 2
- 108090000015 Mesothelin Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- 102000000804 Pregnane X Receptor Human genes 0.000 description 2
- 108010001511 Pregnane X Receptor Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000011374 additional therapy Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 230000007614 genetic variation Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 239000007791 liquid phase Substances 0.000 description 2
- 238000001325 log-rank test Methods 0.000 description 2
- 238000007403 mPCR Methods 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000007838 multiplex ligation-dependent probe amplification Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 238000007858 polymerase cycling assembly Methods 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229940113082 thymine Drugs 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000000107 tumor biomarker Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 206010058897 Adnexa uteri mass Diseases 0.000 description 1
- 244000153158 Ammi visnaga Species 0.000 description 1
- 235000010585 Ammi visnaga Nutrition 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 108091007743 BRCA1/2 Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 190000008236 Carboplatin Chemical compound 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000003844 DNA helicases Human genes 0.000 description 1
- 108090000133 DNA helicases Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 101150112014 Gapdh gene Proteins 0.000 description 1
- 102000010956 Glypican Human genes 0.000 description 1
- 108050001154 Glypican Proteins 0.000 description 1
- 108050007237 Glypican-3 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101001062222 Homo sapiens Receptor-binding cancer antigen expressed on SiSo cells Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000005722 Mammaglobin B Human genes 0.000 description 1
- 108010031029 Mammaglobin B Proteins 0.000 description 1
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 1
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 108091092878 Microsatellite Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 102100029165 Receptor-binding cancer antigen expressed on SiSo cells Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038111 Recurrent cancer Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 108700009124 Transcription Initiation Site Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- 238000007845 assembly PCR Methods 0.000 description 1
- 238000007846 asymmetric PCR Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000012707 chemical precursor Substances 0.000 description 1
- 239000012568 clinical material Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007847 digital PCR Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 102000056553 human SPA17 Human genes 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000009830 intercalation Methods 0.000 description 1
- 238000007852 inverse PCR Methods 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000007862 touchdown PCR Methods 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000012447 xenograft mouse model Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57473—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving carcinoembryonic antigen, i.e. CEA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161535309P | 2011-09-15 | 2011-09-15 | |
| US61/535,309 | 2011-09-15 | ||
| PCT/US2012/054914 WO2013040071A2 (en) | 2011-09-15 | 2012-09-12 | Sperm protein as a detection biomarker of early stage ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2848578A1 true CA2848578A1 (en) | 2013-03-21 |
Family
ID=47883948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2848578 Abandoned CA2848578A1 (en) | 2011-09-15 | 2012-09-12 | Sperm protein as a detection biomarker of early stage ovarian cancer |
Country Status (7)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104807997A (zh) * | 2015-05-05 | 2015-07-29 | 南京格耀生物科技有限公司 | 一种基于化学发光法检测ca125和sp17含量的试剂盒及方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7405077B2 (en) * | 2001-02-26 | 2008-07-29 | Albany Medical College | Sperm protein 17 for the diagnosis and treatment of cancer |
| US7189507B2 (en) * | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| AT501348B1 (de) * | 2005-01-31 | 2008-10-15 | Vitateq Biotechnology Gmbh | Verfahren zur tumordiagnose |
| CN100334110C (zh) * | 2005-09-01 | 2007-08-29 | 中国人民解放军南京军区南京总医院 | 一种精子蛋白单克隆抗体及其制备方法和用途 |
| DE602006015508D1 (de) * | 2005-11-16 | 2010-08-26 | Pantarhei Bioscience Bv | Pharmazeutische zusammensetzung zur behandlung oder prävention von ovarialkrebs |
-
2012
- 2012-09-12 WO PCT/US2012/054914 patent/WO2013040071A2/en active Application Filing
- 2012-09-12 IN IN2496CHN2014 patent/IN2014CN02496A/en unknown
- 2012-09-12 CN CN201280054743.6A patent/CN104039980A/zh active Pending
- 2012-09-12 CA CA 2848578 patent/CA2848578A1/en not_active Abandoned
- 2012-09-12 US US14/345,208 patent/US20150110897A1/en not_active Abandoned
- 2012-09-12 JP JP2014530760A patent/JP2014527816A/ja active Pending
- 2012-09-12 EP EP12831144.6A patent/EP2756100A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013040071A3 (en) | 2013-05-10 |
| WO2013040071A2 (en) | 2013-03-21 |
| CN104039980A (zh) | 2014-09-10 |
| IN2014CN02496A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2015-06-19 |
| US20150110897A1 (en) | 2015-04-23 |
| JP2014527816A (ja) | 2014-10-23 |
| EP2756100A2 (en) | 2014-07-23 |
| EP2756100A4 (en) | 2015-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10113202B2 (en) | Method for determining the methylation status of the promoter region of the TWIST1 gene in genomic DNA from bladder cells | |
| US10196687B2 (en) | Molecular diagnosis and typing of lung cancer variants | |
| US20140336280A1 (en) | Compositions and methods for detecting and determining a prognosis for prostate cancer | |
| JP2017532959A (ja) | Ｍｄｍ２阻害剤に対する感受性の遺伝子シグネチャーに基づく予測因子に関するアルゴリズム | |
| JP2017508442A (ja) | Ｍｄｍ２阻害剤に対する感受性と関連する遺伝子シグネチャー | |
| CN103097548A (zh) | 基于多癌症侵袭相关机制的生物标记 | |
| US20110223180A1 (en) | Methods and compositions related to a multi-methylation assay to predict patient outcome | |
| Rogers et al. | Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs | |
| JP7733581B2 (ja) | 膵臓癌を診断するための高メチル化遺伝子の検出 | |
| US20110183862A1 (en) | Molecular signature of liver tumor grade and use to evaluate prognosis and therapeutic regimen | |
| US20210404018A1 (en) | Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer | |
| JP6145083B2 (ja) | Ｊａｋ２核酸中の変異を検出するための組成物および方法 | |
| JP2022536846A (ja) | 胃癌を診断するための高メチル化遺伝子の検出 | |
| Yu et al. | Arms-qPCR improves detection sensitivity of earlier diagnosis of papillary thyroid cancers with worse prognosis determined by coexisting BRAF V600E and Tert promoter mutations | |
| WO2013144202A1 (en) | Biomarkers for discriminating healthy and/or non-malignant neoplastic colorectal cells from colorectal cancer cells | |
| JP6876304B2 (ja) | 癌に対する薬物療法の効果の予測方法 | |
| US20150110897A1 (en) | Sperm Protein as a Detection Biomarker of Early Stage Ovarian Cancer | |
| KR102384992B1 (ko) | 대장암 환자의 연령 특이적 바이오마커 및 이의 용도 | |
| WO2014160829A2 (en) | Unbiased dna methylation markers define an extensive field defect in histologically normal porstate tissues associated with prostate cancer: new biomarkers for men with prostate cancer | |
| WO2013173476A1 (en) | Detection of cancer | |
| EP3464620A1 (en) | Determination of genetic predisposition to aggressive prostate cancer | |
| US20130122494A1 (en) | Detection of cancer | |
| JP2025039500A (ja) | 子宮内膜がん患者の臨床的転帰を予測する方法、予測装置、予測プログラム、検査試薬、及び検査キット | |
| NZ748621B2 (en) | Determination of genetic predisposition to aggressive prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |
Effective date: 20170912 |